889 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
tu2218 Neoplasm	TiumBio Co., Ltd.	P1/2	CC (40)
Tyra-300 Neoplasm	Tyra Biosciences, Inc	P1/2	CC (40)
Vert-002 Neoplasm	Pierre Fabre Medicament	P1/2	CC (40)
vip236 Neoplasm	Vincerx Pharma, Inc.	P1	CC (40)
Vodudeutentan Sodium Neoplasm	ENB Therapeutics, Inc	P1/2	CC (40)
Vorbipiprant Neoplasm	Rottapharm Biotech	P1/2	CC (40)
Vsv-Ifnβ-Nis Neoplasm	Vyriad, Inc.	P1/2	CC (40)
XS-02 Neoplasm	NovaOnco Therapeutics Co., Ltd.	P1/2	CC (40)
yh42946 Neoplasm	Yuhan Corporation	P1/2	CC (40)
zg005 Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
zg006 Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
zg2001 tosilate tablets Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
ak119 Neoplasm	Akeso	P1	C (39)
am003 Neoplasm	Aummune Ltd.	P1	C (39)
Asca101 Neoplasm	MetaFines	P1	C (39)
asn004 Neoplasm	Kirilys Therapeutics Inc.	P1	C (39)
Astx 660 Neoplasm	Taiho Oncology, Inc.	P1/2	C (39)
Byon3521 Neoplasm	Byondis B.V.	P1	C (39)
Car-Nk Cell Neoplasm	The Second Hospital of Shandong University	Early P1	C (39)
dt2216 Neoplasm	Dialectic Therapeutics, Inc	P1	C (39)
dz-002 Neoplasm	Da Zen Theranostics Inc	P1	C (39)
Fapi-46 Neoplasm	Eben Rosenthal	Early P1	C (39)
Fuzuloparib Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P1	C (39)
hcw9218 Neoplasm	Masonic Cancer Center, University of Minnesota	P1	C (39)
hh-101 Neoplasm	Huahui Health	P1	C (39)
ibi325 Neoplasm	Shandong Cancer Hospital and Institute	P1	C (39)
Igm-7354 Neoplasm	IGM Biosciences, Inc.	P1	C (39)
lp-118 Neoplasm	Guangzhou Lupeng Pharmaceutical Company LTD.	P1	C (39)
Magrolimab Neoplasm	Gilead Sciences	P2	C (39)
rp12146 Neoplasm	Rhizen Pharmaceuticals SA	P1	C (39)
s095029 Neoplasm	Institut de Recherches Internationales Servier	P1	C (39)
Sail66 Neoplasm	Chugai Pharmaceutical	P1	C (39)
snk02 Neoplasm	NKGen Biotech, Inc.	P1	C (39)
Tovorafenib Neoplasm	Day One Biopharmaceuticals, Inc.	P2	C (39)
Tuvusertib Neoplasm	Institut Curie	P1	C (39)
YH 001 Neoplasm	Eucure (Beijing) Biopharma Co., Ltd	P1	C (39)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) Neoplasm	Eucure (Beijing) Biopharma Co., Ltd	P1	C (39)
Yzj-5053 Tablets Neoplasm	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	P1	C (39)
18F-FAPI-04 Neoplasm	Afﬁliated Hospital of North Sichuan Medical College	Early P1	C (38)
Azenosertib Neoplasm	M.D. Anderson Cancer Center	P1	C (38)
Bemarituzumab Neoplasm	Amgen	P1/2	C (38)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Neoplasm	Institut Curie	P1	C (38)
Tumor Neoantigen Specific T Cell Neoplasm	JIANG LONGWEI	Early P1	C (38)
5-AZA-T-DCYD Neoplasm	National Cancer Institute (NCI)	P1	C (37)
Abbv-303 Neoplasm	AbbVie	P1	C (37)
Adrx-0405 Neoplasm	Adcentrx Therapeutics	P1	C (37)
Adrx-0706 Neoplasm	Adcentrx Therapeutics	P1	C (37)
Ami-Hc Neoplasm	Janssen Research & Development, LLC	P1	C (37)
Ami-Hc-Cf Neoplasm	Janssen Research & Development, LLC	P1	C (37)
Ami-Lc Neoplasm	Janssen Research & Development, LLC	P1	C (37)

Showing 501 to 550 of 889 assets

PreviousPage 11 of 18Next